Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Cash balance of $301.2M expected to fund operations into 2025 CAMBRIDGE, Mass., Nov. 03, 2022…
Month: November 2022
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq:…
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics”…
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Nov. 03,…
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
Data From CPI-818 T Cell Lymphoma Study Accepted for Presentation at the 64th ASH Annual…
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
— NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business,…
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or…
Codexis Reports Third Quarter 2022 Financial Results
Reiterates 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Nov….
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve…
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
— Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application…
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022
– Approximately $61 Million of International Sales in the Third Quarter – – Corporate Update…
RVL Pharmaceuticals plc to Discuss Third Quarter 2022 Financial Results and Provide Commercial Update
— Conference call to be held Thursday, November 10, 2022, at 4:30 p.m. ET —…
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to…
Talis Biomedical Reports Third Quarter 2022 Financial Results
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
–Announced that the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary…
DICE Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE),…
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
– On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in…
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
• AMELI-01 (evaluating UCART123) abstract, selected for oral presentation, highlights that adding alemtuzumab was associated…
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
– Biomedical Advanced Research and Development Authority (BARDA) awarded contract to support pandemic preparedness for…